IMGENEX INDIA combines ScFv engineering, nanobody (VHH) platforms, and AI-driven antibody design to accelerate discovery and deliver next-generation therapeutics with improved developability, specificity, and manufacturing efficiency.
ScFv
Single-chain variable fragments that retain antigen-binding specificity in a compact, engineerable format.
Learn more →Nanobodies
Compact VHH single-domain antibodies with superior tissue penetration and cryptic epitope access.
Learn more →AI designed antibodies
Machine learning and structural modeling to accelerate antibody discovery and optimization.
Learn more →